{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:33:40Z","timestamp":1779928420211,"version":"3.53.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009510.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"reference-count":117,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009510.pub3","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T16:20:01Z","timestamp":1594138801000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion"],"prefix":"10.1002","volume":"2020","author":[{"given":"Zaid","family":"Shalchi","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; London UK"},{"name":"Royal Berkshire NHS Foundation Trust; Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mahroo","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[{"name":"London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Mitry","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; London UK"},{"name":"Royal Free Hospital, NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"697-705","DOI":"10.1177\/1120672117750058","article-title":"A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion","volume":"28","author":"Bandello","year":"2018","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0002|cit2","unstructured":"A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX\u00ae versus Lucentis\u00ae in patients with branch retinal vein occlusion www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-023900-29\/results"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0003|cit3","unstructured":"Safety and efficacy study of Ozurdex\u00ae compared to Lucentis\u00ae in patients with branch retinal vein occlusion clinicaltrials.gov\/ct2\/show\/NCT01427751"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0004|cit4","unstructured":"Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom) ClinicalTrials.gov\/show\/NCT01976338"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0005|cit5","unstructured":"Wei W To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Annual Meeting of the Association for Research in Vision and Ophthalmology 2017"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","article-title":"Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER","volume":"123","author":"Tadayoni","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","volume":"96","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmologica"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1755-3768.2011.02298.x","article-title":"Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion","volume":"91","author":"Higashiyama","year":"2013","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/aos.12488","article-title":"Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial","volume":"93","author":"Pielen","year":"2015","journal-title":"Acta Ophthalmologica"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-012-1941-8","article-title":"Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion","volume":"250","author":"Ramezani","year":"2012","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Molecular Therapy"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2010.03.060","article-title":"Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00417-015-2947-9","article-title":"Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study","volume":"253","author":"Chiquet","year":"2015","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000442258","article-title":"Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up","volume":"55","author":"Chiquet","year":"2016","journal-title":"Ophthalmic Research"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1111\/aos.13770","article-title":"Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study","volume":"96","author":"Feltgen","year":"2018","journal-title":"Acta Ophthalmologica"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3928\/23258160-20150909-09","article-title":"Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study","volume":"46","author":"Rajagopal","year":"2015","journal-title":"Ophthalmic Surgery, Lasers & Imaging Retina"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5301\/ejo.5000085","article-title":"Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion","volume":"22","author":"Donati","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000458534","article-title":"Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population","volume":"58","author":"Gu","year":"2017","journal-title":"Ophthalmic Research"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000350812","article-title":"Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion","volume":"230","author":"Guignier","year":"2013","journal-title":"Ophthalmologica"},{"issue":"1-2","key":"10.1002\/14651858.CD009510.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000473864","article-title":"Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions","volume":"238","author":"Hanhart","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2147\/OPTH.S116745","article-title":"Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion","volume":"10","author":"Kartasasmita","year":"2016","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"A 419","DOI":"10.1016\/j.jval.2015.09.549","article-title":"Cost effectiveness analysis of ranibizumab compared to aflibercept and laser intervention In treatment of diabetic macular edema (DME) In the Czech Republic","volume":"18","author":"Klimes","year":"2015","journal-title":"Value in Health"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2012-301992","article-title":"Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design","volume":"97","author":"Leitritz","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD009510.pub3-BIB0029|cit29","first-page":"2006","article-title":"Clinical therapeutic effects of intravitreal Ranibizumab injection combined laser photocoagulation for macular edema in BRVO","volume":"14","author":"Liu","year":"2014","journal-title":"Guoji Yanke Zazhi"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"954-9","DOI":"10.1136\/bjophthalmol-2014-306543","article-title":"A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1","volume":"99","author":"Narayanan","year":"2015","journal-title":"British Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/eye.2016.96","article-title":"Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion","volume":"30","author":"Moon","year":"2016","journal-title":"Eye"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00417-010-1440-8","article-title":"Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)","volume":"249","author":"Moradian","year":"2011","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1111\/aos.12317","article-title":"Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion","volume":"92","author":"Ramezani","year":"2014","journal-title":"Acta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e007527","DOI":"10.1136\/bmjopen-2014-007527","article-title":"Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis","volume":"5","author":"Regnier","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/IAE.0b013e318195ca65","article-title":"Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion","volume":"29","author":"Russo","year":"2009","journal-title":"Retina"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ophtha.2014.06.011","article-title":"Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajo.2013.08.013","article-title":"Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion","volume":"157","author":"Tan","year":"2014","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1111\/aos.12721","article-title":"Comparative study of combined bevacizumab\/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions","volume":"94","author":"Tomomatsu","year":"2016","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2009.08.005","article-title":"Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion","volume":"149","author":"Wroblewski","year":"2010","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0040|cit40","first-page":"747","article-title":"Observation on intravitreal injection of ranibizumab combined with laser photocoagulation for the treatment of macular edema in BRVO","volume":"14","author":"Zhang","year":"2014","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0041|cit41","unstructured":"Comparison of intravitreal ranibizumab and macular laser photocoagulation for ME following branch retinal vein occlusion (BRVO) clinicaltrials.gov\/ct2\/show\/NCT01189526"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0042|cit42","unstructured":"Ranibizumab for macular edema secondary to branch retinal vein occlusion in patients with fair vision (RVOFV) clinicaltrials.gov\/ct2\/show\/NCT01795209"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0043|cit43","unstructured":"Conbercept ophthalmic injection for patients with macular edema caused by branch retinal vein occlusion clinicaltrials.gov\/ct2\/show\/NCT03108352"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2415-8-18","article-title":"Treatment of branch retinal vein occlusion induced macular edema with bevacizumab","volume":"8","author":"Abegg","year":"2008","journal-title":"BMC Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3129\/i09-040","article-title":"The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion","volume":"44","author":"Ahmadi","year":"2009","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"23","key":"10.1002\/14651858.CD009510.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"Aiello","year":"1995","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2007.135913","article-title":"Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire","volume":"94","author":"Awdeh","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"98","author":"The Branch Vein Occlusion Study Group","year":"1984","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2007.0012","article-title":"Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema","volume":"23","author":"Byeon","year":"2007","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00417-010-1320-2","article-title":"Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion","volume":"248","author":"Byun","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/02713683.2010.496540","article-title":"A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion","volume":"35","author":"Cekic","year":"2010","journal-title":"Current Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0055|cit55","first-page":"424","article-title":"Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection","volume":"33","author":"Chen","year":"2010","journal-title":"Chang Gung Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD009510.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/eye.2009.230","article-title":"Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion","volume":"23","author":"Cheng","year":"2009","journal-title":"Eye"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00417-008-0866-8","article-title":"Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion","volume":"246","author":"Chung","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0058|cit58","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.66.3.161","article-title":"Retinal vein occlusion and the prevalence of lipoprotein abnormalities","volume":"66","author":"Dodson","year":"1982","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/eye.1992.13","article-title":"Diabetes mellitus and retinal vein occlusion in patients of Asian, West Indian and white European origin","volume":"6","author":"Dodson","year":"1992","journal-title":"Eye"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9394(14)71345-5","article-title":"Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group","volume":"116","year":"1993","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","article-title":"Retinal vein occlusion: beyond the acute event","volume":"56","author":"Ehlers","year":"2011","journal-title":"Survey of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions","volume":"94","author":"Figueroa","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archopht.1982.01030040110020","article-title":"Histopathologic study of nine branch retinal vein occlusions","volume":"100","author":"Frangieh","year":"1982","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","volume":"50","author":"Funk","year":"2009","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0067|cit67","first-page":"455","article-title":"Ranibizumab: in macular oedema following retinal vein occlusion","volume":"71","author":"Garnock-Jones","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0161-6420(96)30653-2","article-title":"Prognostic factors for retinal vein occlusion: prospective study of 175 cases","volume":"103","author":"Glacet-Bernard","year":"1996","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0069|cit69","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0070|cit70","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editors The GRADE Working Group GRADE Handbook for grading quality of evidence and strength of recommendations gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0071|cit71","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"27","key":"10.1002\/14651858.CD009510.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/IAE.0b013e3181aa8dfe","article-title":"Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion","volume":"29","author":"Gregori","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.eye.6703040","article-title":"Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion","volume":"22","author":"Gunduz","year":"2008","journal-title":"Eye"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0076|cit76","first-page":"1013","article-title":"Effect of repeated intravitreal bevacizumab injections for secondary macular edema of branch retinal vein occlusion","volume":"114","author":"Hara","year":"2010","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00417-009-1151-1","article-title":"Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion","volume":"247","author":"Hoeh","year":"2009","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"22","key":"10.1002\/14651858.CD009510.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.004","article-title":"Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study","volume":"122","author":"Hou","year":"2009","journal-title":"Chinese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2009.0090","article-title":"Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion","volume":"26","author":"Hung","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","article-title":"One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion","volume":"247","author":"Jaissle","year":"2009","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00417-010-1470-2","article-title":"Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion","volume":"249","author":"Jaissle","year":"2011","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0083|cit83","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Archives of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/IAE.0b013e3181aa8e20","article-title":"Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis","volume":"29","author":"Kondo","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.clinthera.2007.09.008","article-title":"Ranibizumab for the treatment of neovascular age-related macular degeneration: a review","volume":"29","author":"Kourlas","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","article-title":"Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion","volume":"92","author":"Kreutzer","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009510.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","article-title":"Interventions for branch retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"McIntosh","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.sjopt.2010.03.004","article-title":"Early Avastin management in acute retinal vein occlusion","volume":"24","author":"Mehany","year":"2010","journal-title":"Saudi Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2011.585394","article-title":"A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab","volume":"27","author":"Mitchell","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","article-title":"Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion","volume":"244","author":"Noma","year":"2006","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1006\/exer.1996.0239","article-title":"Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates","volume":"64","author":"Ozaki","year":"1997","journal-title":"Experimental Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","article-title":"Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion","volume":"143","author":"Pai","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/bjo.2009.174060","article-title":"Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up","volume":"95","author":"Pece","year":"2011","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"British Journal of Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD009510.pub3-BIB0099|cit99","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD009510.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jcpt.12551","article-title":"Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis","volume":"42","author":"Qian","year":"2017","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion","volume":"27","author":"Rabena","year":"2007","journal-title":"Retina"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities","volume":"33","author":"Rehak","year":"2008","journal-title":"Current Eye Research"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000183844","article-title":"Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion","volume":"223","author":"Rensch","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD009510.pub3-BIB0104|cit104","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD009510.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/IAE.0b013e3181cd4894","article-title":"Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study","volume":"30","author":"Rouvas","year":"2010","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00347-007-1509-x","article-title":"Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion","volume":"104","author":"Schaal","year":"2007","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bjo.60.12.810","article-title":"New vessel formation in retinal branch vein occlusion","volume":"60","author":"Shilling","year":"1976","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00417-007-0569-6","article-title":"Bevacizumab in retinal vein occlusion-results of a prospective case series","volume":"245","author":"Stahl","year":"2007","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ajo.2007.07.015","article-title":"Retinal vein occlusions and mortality: the Beijing Eye Study","volume":"144","author":"Xu","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1167\/iovs.09-4453","article-title":"Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study","volume":"51","author":"Yasuda","year":"2010","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub3-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009510","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","author":"Mitry","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub3-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009510.pub2","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","author":"Mitry","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T12:57:54Z","timestamp":1723208274000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009510.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":117,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009510.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}